Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | NEK2 | P51955 | 8/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314734 | 0.98 | TSHR (0.68) | POLBTSHRNEK2AURKACDK1 | |
| SCHEMBL3576095 | 0.81 | POLB (0.72) | POLBTSHRNEK2AURKACDK1 | |
| SCHEMBL4514851 | 0.81 | POLB (0.72) | POLBTSHRNEK2AURKACDK1 | |
| SCHEMBL8085658 | 0.81 | POLB (0.72) | POLBTSHRNEK2AURKACDK1 | |
| SCHEMBL12911751 | 0.81 | POLB (0.72) | POLBTSHRNEK2AURKACDK1 | |
| SCHEMBL951124 | 0.80 | TSHR (0.72) | POLBTSHRNEK2AURKACDK1 | |
| SCHEMBL3306850 | 0.80 | TSHR (0.72) | POLBTSHRNEK2AURKACDK1 | |
| SCHEMBL13059638 | 0.80 | TSHR (0.72) | POLBTSHRNEK2AURKACDK1 | |
| SCHEMBL4598371 | 0.80 | TSHR (0.72) | POLBTSHRNEK2AURKACDK1 | |
| SCHEMBL13272812 | 0.80 | TSHR (1.00) | POLBTSHRNEK2AURKACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113545-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | COULTON STEVEN | 2010-05-06 | — | — | US | disclosed |
| US-20100113545-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | COULTON STEVEN | 2010-05-06 | — | — | US | disclosed |
| US-20100113545-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | COULTON STEVEN | 2010-05-06 | — | — | US | disclosed |
| EP-2121622-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008092872-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092872-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113545-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SLC18A2, SLC6A5, SLC6A2 | POLB 4461/4885TSHR 1553/4885NEK2 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.